Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Operating Leases (2023 - 2026)

bioAffinity Technologies has reported Operating Leases over the past 4 years, most recently at $687460.0 for Q1 2026.

  • Quarterly Operating Leases rose 122.9% to $687460.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $687460.0 through Mar 2026, up 122.9% year-over-year, with the annual reading at $202878.0 for FY2025, 40.7% down from the prior year.
  • Operating Leases was $687460.0 for Q1 2026 at bioAffinity Technologies, up from $202878.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $687460.0 in Q1 2026 and troughed at $202878.0 in Q4 2025.
  • The 4-year median for Operating Leases is $331307.0 (2024), against an average of $363906.1.
  • Year-over-year, Operating Leases crashed 40.7% in 2025 and then surged 122.9% in 2026.
  • A 4-year view of Operating Leases shows it stood at $283001.0 in 2023, then rose by 20.88% to $342098.0 in 2024, then crashed by 40.7% to $202878.0 in 2025, then skyrocketed by 238.85% to $687460.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Operating Leases are $687460.0 (Q1 2026), $202878.0 (Q4 2025), and $375139.0 (Q3 2025).